Ascendis Pharma Reports Strong 2025 Financials, Driven by YORVIPATH Sales & Pipeline Progress; Announces $120M Share Repurchase
Summary
Ascendis Pharma A/S filed its annual 20-F, reporting significantly increased revenue and positive operating cash flow for 2025, driven by strong commercial performance of YORVIPATH and SKYTROFA, alongside key pipeline advancements and a new $120 million share repurchase program.
Key Events
-
Strong 2025 Financial Performance
Revenue increased to €720.1 million in 2025 from €363.6 million in 2024, and operating cash flow turned positive at €53.9 million, a significant improvement from a €306.2 million loss in 2024.
-
YORVIPATH Commercial Success
YORVIPATH (TransCon PTH) sales surged to €477.4 million in 2025 from €28.7 million in 2024, following its US launch in late 2024 and Japan launch in November 2025.
-
SKYTROFA Global Expansion
SKYTROFA (TransCon hGH) received approval in China in January 2026 and continued to grow sales to €206.2 million in 2025.
-
Advanced Pipeline & Regulatory Milestones
TransCon CNP's NDA for achondroplasia was accepted for priority review by the FDA with a PDUFA date of February 28, 2026, and its MAA was submitted to the EMA. Positive topline results from the COACH combination therapy trial were also reported in January 2026.
Analysis
The annual 20-F filing highlights a period of substantial commercial growth and pipeline advancement for Ascendis Pharma. The significant increase in revenue and the shift to positive operating cash flow demonstrate improving financial health and successful market penetration of its approved products, particularly YORVIPATH. The upcoming PDUFA date for TransCon CNP and positive clinical data for its combination therapy underscore continued pipeline momentum. The new share repurchase program signals management's confidence in the company's valuation and future prospects. While the company still reports a net loss and an equity deficit, the strong operational performance and strategic initiatives indicate a positive trajectory for investors.
At the time of this filing, ASND was trading at $216.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.7B. The 52-week trading range was $118.03 to $242.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.